NO302622B1 - Rekombinant vektor, vertsorganisme, fremgangsmåte for fremstilling av et fullengde PIA protein fra Neisseria gonorrhoeae - Google Patents
Rekombinant vektor, vertsorganisme, fremgangsmåte for fremstilling av et fullengde PIA protein fra Neisseria gonorrhoeae Download PDFInfo
- Publication number
- NO302622B1 NO302622B1 NO902251A NO902251A NO302622B1 NO 302622 B1 NO302622 B1 NO 302622B1 NO 902251 A NO902251 A NO 902251A NO 902251 A NO902251 A NO 902251A NO 302622 B1 NO302622 B1 NO 302622B1
- Authority
- NO
- Norway
- Prior art keywords
- protein
- pia
- gene
- plasmid
- pib
- Prior art date
Links
- 101710167887 Major outer membrane protein P.IA Proteins 0.000 title claims description 118
- 239000013598 vector Substances 0.000 title claims description 50
- 238000004519 manufacturing process Methods 0.000 title description 24
- 241000588652 Neisseria gonorrhoeae Species 0.000 title description 19
- 108090000623 proteins and genes Proteins 0.000 claims description 161
- 101710167885 Major outer membrane protein P.IB Proteins 0.000 claims description 93
- 102000004169 proteins and genes Human genes 0.000 claims description 75
- 238000000034 method Methods 0.000 claims description 74
- 239000013612 plasmid Substances 0.000 claims description 57
- 230000014509 gene expression Effects 0.000 claims description 25
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 20
- 206010018612 Gonorrhoea Diseases 0.000 claims description 16
- 241000588653 Neisseria Species 0.000 claims description 13
- 230000001939 inductive effect Effects 0.000 claims description 10
- 238000012258 culturing Methods 0.000 claims description 9
- 238000013519 translation Methods 0.000 claims description 9
- 239000000411 inducer Substances 0.000 claims description 8
- 238000013518 transcription Methods 0.000 claims description 8
- 230000035897 transcription Effects 0.000 claims description 8
- 108020004707 nucleic acids Proteins 0.000 claims description 7
- 102000039446 nucleic acids Human genes 0.000 claims description 7
- 150000007523 nucleic acids Chemical class 0.000 claims description 7
- 230000001105 regulatory effect Effects 0.000 claims description 4
- 230000008569 process Effects 0.000 claims description 2
- 230000002103 transcriptional effect Effects 0.000 claims description 2
- 239000012634 fragment Substances 0.000 description 90
- 108020004414 DNA Proteins 0.000 description 73
- 235000018102 proteins Nutrition 0.000 description 68
- 210000004027 cell Anatomy 0.000 description 49
- 229960005486 vaccine Drugs 0.000 description 40
- 101150082998 pi gene Proteins 0.000 description 34
- 239000000203 mixture Substances 0.000 description 30
- 108091034117 Oligonucleotide Proteins 0.000 description 29
- 239000000047 product Substances 0.000 description 29
- 150000001413 amino acids Chemical group 0.000 description 26
- 239000000427 antigen Substances 0.000 description 22
- 108091007433 antigens Proteins 0.000 description 22
- 102000036639 antigens Human genes 0.000 description 22
- 108010035563 Chloramphenicol O-acetyltransferase Proteins 0.000 description 19
- 238000010367 cloning Methods 0.000 description 19
- 238000009396 hybridization Methods 0.000 description 19
- 239000000523 sample Substances 0.000 description 19
- 125000003729 nucleotide group Chemical group 0.000 description 17
- 241000588724 Escherichia coli Species 0.000 description 16
- 208000015181 infectious disease Diseases 0.000 description 16
- 239000002773 nucleotide Substances 0.000 description 16
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 15
- 108091008146 restriction endonucleases Proteins 0.000 description 14
- 238000002955 isolation Methods 0.000 description 13
- BPHPUYQFMNQIOC-NXRLNHOXSA-N isopropyl beta-D-thiogalactopyranoside Chemical compound CC(C)S[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O BPHPUYQFMNQIOC-NXRLNHOXSA-N 0.000 description 13
- 244000005700 microbiome Species 0.000 description 13
- 238000012163 sequencing technique Methods 0.000 description 13
- 238000002360 preparation method Methods 0.000 description 12
- 238000002105 Southern blotting Methods 0.000 description 11
- 235000001014 amino acid Nutrition 0.000 description 11
- 229940024606 amino acid Drugs 0.000 description 11
- 238000003776 cleavage reaction Methods 0.000 description 11
- 230000001681 protective effect Effects 0.000 description 11
- 230000007017 scission Effects 0.000 description 11
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 10
- 108010076504 Protein Sorting Signals Proteins 0.000 description 10
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 10
- 108020004511 Recombinant DNA Proteins 0.000 description 9
- 238000010276 construction Methods 0.000 description 9
- 239000000499 gel Substances 0.000 description 9
- 239000000872 buffer Substances 0.000 description 8
- 230000000295 complement effect Effects 0.000 description 8
- 230000036039 immunity Effects 0.000 description 8
- 239000003550 marker Substances 0.000 description 8
- 239000012528 membrane Substances 0.000 description 8
- 230000014616 translation Effects 0.000 description 8
- 108020005187 Oligonucleotide Probes Proteins 0.000 description 7
- 101710190786 PI protein Proteins 0.000 description 7
- 230000015572 biosynthetic process Effects 0.000 description 7
- 238000011161 development Methods 0.000 description 7
- 201000010099 disease Diseases 0.000 description 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 7
- 230000002163 immunogen Effects 0.000 description 7
- 238000003780 insertion Methods 0.000 description 7
- 230000037431 insertion Effects 0.000 description 7
- 239000000463 material Substances 0.000 description 7
- 239000002751 oligonucleotide probe Substances 0.000 description 7
- 230000009466 transformation Effects 0.000 description 7
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 6
- 239000000020 Nitrocellulose Substances 0.000 description 6
- 238000007792 addition Methods 0.000 description 6
- 230000001580 bacterial effect Effects 0.000 description 6
- 238000006243 chemical reaction Methods 0.000 description 6
- 239000013599 cloning vector Substances 0.000 description 6
- 108020001507 fusion proteins Proteins 0.000 description 6
- 102000037865 fusion proteins Human genes 0.000 description 6
- 239000002609 medium Substances 0.000 description 6
- 229920001220 nitrocellulos Polymers 0.000 description 6
- 238000000746 purification Methods 0.000 description 6
- 230000004044 response Effects 0.000 description 6
- 238000011282 treatment Methods 0.000 description 6
- 238000011144 upstream manufacturing Methods 0.000 description 6
- 108091026890 Coding region Proteins 0.000 description 5
- 102000053602 DNA Human genes 0.000 description 5
- 102000004190 Enzymes Human genes 0.000 description 5
- 108090000790 Enzymes Proteins 0.000 description 5
- 230000000890 antigenic effect Effects 0.000 description 5
- 238000001514 detection method Methods 0.000 description 5
- 208000001786 gonorrhea Diseases 0.000 description 5
- 229910001629 magnesium chloride Inorganic materials 0.000 description 5
- 108090000765 processed proteins & peptides Proteins 0.000 description 5
- 230000000717 retained effect Effects 0.000 description 5
- 239000011780 sodium chloride Substances 0.000 description 5
- 241000894006 Bacteria Species 0.000 description 4
- 241000701867 Enterobacteria phage T7 Species 0.000 description 4
- 125000001429 N-terminal alpha-amino-acid group Chemical group 0.000 description 4
- 239000011543 agarose gel Substances 0.000 description 4
- 230000003115 biocidal effect Effects 0.000 description 4
- 150000001875 compounds Chemical class 0.000 description 4
- 230000000875 corresponding effect Effects 0.000 description 4
- 238000003745 diagnosis Methods 0.000 description 4
- 238000002405 diagnostic procedure Methods 0.000 description 4
- 239000005546 dideoxynucleotide Substances 0.000 description 4
- 239000013604 expression vector Substances 0.000 description 4
- 238000009472 formulation Methods 0.000 description 4
- 210000000987 immune system Anatomy 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 238000006467 substitution reaction Methods 0.000 description 4
- 238000003786 synthesis reaction Methods 0.000 description 4
- 238000001262 western blot Methods 0.000 description 4
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 108700028369 Alleles Proteins 0.000 description 3
- 102100034613 Annexin A2 Human genes 0.000 description 3
- 108090000668 Annexin A2 Proteins 0.000 description 3
- 108700010070 Codon Usage Proteins 0.000 description 3
- 102000012410 DNA Ligases Human genes 0.000 description 3
- 108010061982 DNA Ligases Proteins 0.000 description 3
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 108090000288 Glycoproteins Proteins 0.000 description 3
- 102000003886 Glycoproteins Human genes 0.000 description 3
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 101710116435 Outer membrane protein Proteins 0.000 description 3
- 108010013381 Porins Proteins 0.000 description 3
- 102000017033 Porins Human genes 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 239000007983 Tris buffer Substances 0.000 description 3
- 125000000539 amino acid group Chemical group 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 235000003704 aspartic acid Nutrition 0.000 description 3
- 230000002238 attenuated effect Effects 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 3
- 230000015556 catabolic process Effects 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 238000006731 degradation reaction Methods 0.000 description 3
- 238000012217 deletion Methods 0.000 description 3
- 230000037430 deletion Effects 0.000 description 3
- VHJLVAABSRFDPM-QWWZWVQMSA-N dithiothreitol Chemical compound SC[C@@H](O)[C@H](O)CS VHJLVAABSRFDPM-QWWZWVQMSA-N 0.000 description 3
- 230000002209 hydrophobic effect Effects 0.000 description 3
- 238000002169 hydrotherapy Methods 0.000 description 3
- 230000028993 immune response Effects 0.000 description 3
- 238000003119 immunoblot Methods 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- 231100000518 lethal Toxicity 0.000 description 3
- 230000001665 lethal effect Effects 0.000 description 3
- 230000000813 microbial effect Effects 0.000 description 3
- 238000002703 mutagenesis Methods 0.000 description 3
- 231100000350 mutagenesis Toxicity 0.000 description 3
- 230000001717 pathogenic effect Effects 0.000 description 3
- 239000013600 plasmid vector Substances 0.000 description 3
- 230000010076 replication Effects 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 230000009885 systemic effect Effects 0.000 description 3
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 3
- QFVHZQCOUORWEI-UHFFFAOYSA-N 4-[(4-anilino-5-sulfonaphthalen-1-yl)diazenyl]-5-hydroxynaphthalene-2,7-disulfonic acid Chemical compound C=12C(O)=CC(S(O)(=O)=O)=CC2=CC(S(O)(=O)=O)=CC=1N=NC(C1=CC=CC(=C11)S(O)(=O)=O)=CC=C1NC1=CC=CC=C1 QFVHZQCOUORWEI-UHFFFAOYSA-N 0.000 description 2
- 229920001817 Agar Polymers 0.000 description 2
- 239000004475 Arginine Substances 0.000 description 2
- 101150076489 B gene Proteins 0.000 description 2
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- 102000004163 DNA-directed RNA polymerases Human genes 0.000 description 2
- 108090000626 DNA-directed RNA polymerases Proteins 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- 241001198387 Escherichia coli BL21(DE3) Species 0.000 description 2
- 241001131785 Escherichia coli HB101 Species 0.000 description 2
- ZHNUHDYFZUAESO-UHFFFAOYSA-N Formamide Chemical compound NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 description 2
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 2
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 2
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 2
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 2
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 2
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 2
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 2
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 2
- 206010024774 Localised infection Diseases 0.000 description 2
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 2
- 239000004472 Lysine Substances 0.000 description 2
- 101710164702 Major outer membrane protein Proteins 0.000 description 2
- 201000005505 Measles Diseases 0.000 description 2
- 108700028353 OmpC Proteins 0.000 description 2
- 108700022034 Opsonin Proteins Proteins 0.000 description 2
- 208000000474 Poliomyelitis Diseases 0.000 description 2
- 108020004682 Single-Stranded DNA Proteins 0.000 description 2
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 2
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 2
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 239000008272 agar Substances 0.000 description 2
- 235000004279 alanine Nutrition 0.000 description 2
- 239000003242 anti bacterial agent Substances 0.000 description 2
- 230000000844 anti-bacterial effect Effects 0.000 description 2
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 2
- 239000013602 bacteriophage vector Substances 0.000 description 2
- 210000004899 c-terminal region Anatomy 0.000 description 2
- 239000001110 calcium chloride Substances 0.000 description 2
- 229910001628 calcium chloride Inorganic materials 0.000 description 2
- 235000011148 calcium chloride Nutrition 0.000 description 2
- 210000000234 capsid Anatomy 0.000 description 2
- 101150055766 cat gene Proteins 0.000 description 2
- 210000000170 cell membrane Anatomy 0.000 description 2
- 210000002421 cell wall Anatomy 0.000 description 2
- 238000000576 coating method Methods 0.000 description 2
- 230000021615 conjugation Effects 0.000 description 2
- 238000011109 contamination Methods 0.000 description 2
- 239000003937 drug carrier Substances 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 235000013922 glutamic acid Nutrition 0.000 description 2
- 239000004220 glutamic acid Substances 0.000 description 2
- 230000001900 immune effect Effects 0.000 description 2
- 238000003018 immunoassay Methods 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 238000009413 insulation Methods 0.000 description 2
- 229960000310 isoleucine Drugs 0.000 description 2
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 2
- 238000013507 mapping Methods 0.000 description 2
- 108020004999 messenger RNA Proteins 0.000 description 2
- 230000002503 metabolic effect Effects 0.000 description 2
- 235000013336 milk Nutrition 0.000 description 2
- 239000008267 milk Substances 0.000 description 2
- 210000004080 milk Anatomy 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000036961 partial effect Effects 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 238000010647 peptide synthesis reaction Methods 0.000 description 2
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 2
- 238000013492 plasmid preparation Methods 0.000 description 2
- 229920003023 plastic Polymers 0.000 description 2
- 239000004033 plastic Substances 0.000 description 2
- 238000002264 polyacrylamide gel electrophoresis Methods 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 238000003127 radioimmunoassay Methods 0.000 description 2
- 201000005404 rubella Diseases 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- FQENQNTWSFEDLI-UHFFFAOYSA-J sodium diphosphate Chemical compound [Na+].[Na+].[Na+].[Na+].[O-]P([O-])(=O)OP([O-])([O-])=O FQENQNTWSFEDLI-UHFFFAOYSA-J 0.000 description 2
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 2
- 229940048086 sodium pyrophosphate Drugs 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 241000894007 species Species 0.000 description 2
- ATHGHQPFGPMSJY-UHFFFAOYSA-N spermidine Chemical compound NCCCCNCCCN ATHGHQPFGPMSJY-UHFFFAOYSA-N 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 235000019818 tetrasodium diphosphate Nutrition 0.000 description 2
- 239000001577 tetrasodium phosphonato phosphate Substances 0.000 description 2
- 238000012546 transfer Methods 0.000 description 2
- 230000017105 transposition Effects 0.000 description 2
- 238000002255 vaccination Methods 0.000 description 2
- 239000004474 valine Substances 0.000 description 2
- 238000012795 verification Methods 0.000 description 2
- 230000001018 virulence Effects 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- 239000012130 whole-cell lysate Substances 0.000 description 2
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 1
- QRXMUCSWCMTJGU-UHFFFAOYSA-L (5-bromo-4-chloro-1h-indol-3-yl) phosphate Chemical compound C1=C(Br)C(Cl)=C2C(OP([O-])(=O)[O-])=CNC2=C1 QRXMUCSWCMTJGU-UHFFFAOYSA-L 0.000 description 1
- 108020004465 16S ribosomal RNA Proteins 0.000 description 1
- OAKPWEUQDVLTCN-NKWVEPMBSA-N 2',3'-Dideoxyadenosine-5-triphosphate Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@H]1CC[C@@H](CO[P@@](O)(=O)O[P@](O)(=O)OP(O)(O)=O)O1 OAKPWEUQDVLTCN-NKWVEPMBSA-N 0.000 description 1
- QENJLXATANVWMR-UHFFFAOYSA-N 2-[(3-amino-3-imino-2-methylpropanethioyl)amino]acetic acid Chemical compound NC(=N)C(C)C(=S)NCC(O)=O QENJLXATANVWMR-UHFFFAOYSA-N 0.000 description 1
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 1
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 1
- 244000144725 Amygdalus communis Species 0.000 description 1
- 206010003445 Ascites Diseases 0.000 description 1
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 1
- 241000972773 Aulopiformes Species 0.000 description 1
- 231100000699 Bacterial toxin Toxicity 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 201000006082 Chickenpox Diseases 0.000 description 1
- 206010008631 Cholera Diseases 0.000 description 1
- 108020004705 Codon Proteins 0.000 description 1
- 108020003215 DNA Probes Proteins 0.000 description 1
- 238000007399 DNA isolation Methods 0.000 description 1
- 108010008286 DNA nucleotidylexotransferase Proteins 0.000 description 1
- 102100033215 DNA nucleotidylexotransferase Human genes 0.000 description 1
- 239000003298 DNA probe Substances 0.000 description 1
- 230000007023 DNA restriction-modification system Effects 0.000 description 1
- 102000016911 Deoxyribonucleases Human genes 0.000 description 1
- 108010053770 Deoxyribonucleases Proteins 0.000 description 1
- 101000878441 Dichelobacter nodosus Type IV major fimbrial protein FimA Proteins 0.000 description 1
- 101000846901 Drosophila melanogaster Fat-body protein 1 Proteins 0.000 description 1
- 241000701959 Escherichia virus Lambda Species 0.000 description 1
- 108060002716 Exonuclease Proteins 0.000 description 1
- 229920001917 Ficoll Polymers 0.000 description 1
- 241000724791 Filamentous phage Species 0.000 description 1
- 108010000916 Fimbriae Proteins Proteins 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 241000274177 Juniperus sabina Species 0.000 description 1
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 1
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 108700018753 Neisseria porin Proteins 0.000 description 1
- 108700006385 OmpF Proteins 0.000 description 1
- 108700026244 Open Reading Frames Proteins 0.000 description 1
- 241000364057 Peoria Species 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 108010033276 Peptide Fragments Proteins 0.000 description 1
- 102000007079 Peptide Fragments Human genes 0.000 description 1
- 239000004353 Polyethylene glycol 8000 Substances 0.000 description 1
- 108010021757 Polynucleotide 5'-Hydroxyl-Kinase Proteins 0.000 description 1
- 102000008422 Polynucleotide 5'-hydroxyl-kinase Human genes 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 108010001267 Protein Subunits Proteins 0.000 description 1
- 102000002067 Protein Subunits Human genes 0.000 description 1
- 108020004518 RNA Probes Proteins 0.000 description 1
- 239000003391 RNA probe Substances 0.000 description 1
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 1
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 1
- 108700008625 Reporter Genes Proteins 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
- 108091081024 Start codon Proteins 0.000 description 1
- 208000037065 Subacute sclerosing leukoencephalitis Diseases 0.000 description 1
- 206010042297 Subacute sclerosing panencephalitis Diseases 0.000 description 1
- 230000024932 T cell mediated immunity Effects 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- 206010043376 Tetanus Diseases 0.000 description 1
- 239000004098 Tetracycline Substances 0.000 description 1
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 1
- 239000004473 Threonine Substances 0.000 description 1
- 102000008579 Transposases Human genes 0.000 description 1
- 108010020764 Transposases Proteins 0.000 description 1
- 208000037386 Typhoid Diseases 0.000 description 1
- 206010046980 Varicella Diseases 0.000 description 1
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 1
- HDRRAMINWIWTNU-NTSWFWBYSA-N [[(2s,5r)-5-(2-amino-6-oxo-3h-purin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl] phosphono hydrogen phosphate Chemical compound C1=2NC(N)=NC(=O)C=2N=CN1[C@H]1CC[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 HDRRAMINWIWTNU-NTSWFWBYSA-N 0.000 description 1
- ARLKCWCREKRROD-POYBYMJQSA-N [[(2s,5r)-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl] phosphono hydrogen phosphate Chemical compound O=C1N=C(N)C=CN1[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)CC1 ARLKCWCREKRROD-POYBYMJQSA-N 0.000 description 1
- 239000003070 absorption delaying agent Substances 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 125000003295 alanine group Chemical group N[C@@H](C)C(=O)* 0.000 description 1
- 229960000723 ampicillin Drugs 0.000 description 1
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 229940121375 antifungal agent Drugs 0.000 description 1
- 239000003429 antifungal agent Substances 0.000 description 1
- 235000009582 asparagine Nutrition 0.000 description 1
- 229960001230 asparagine Drugs 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 239000012298 atmosphere Substances 0.000 description 1
- 229940031567 attenuated vaccine Drugs 0.000 description 1
- 239000000688 bacterial toxin Substances 0.000 description 1
- 230000000721 bacterilogical effect Effects 0.000 description 1
- 101150049515 bla gene Proteins 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 229940098773 bovine serum albumin Drugs 0.000 description 1
- 239000006227 byproduct Substances 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 229960005091 chloramphenicol Drugs 0.000 description 1
- WIIZWVCIJKGZOK-RKDXNWHRSA-N chloramphenicol Chemical compound ClC(Cl)C(=O)N[C@H](CO)[C@H](O)C1=CC=C([N+]([O-])=O)C=C1 WIIZWVCIJKGZOK-RKDXNWHRSA-N 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- -1 coatings Substances 0.000 description 1
- 238000004440 column chromatography Methods 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 101150054175 cro gene Proteins 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- URGJWIFLBWJRMF-JGVFFNPUSA-N ddTTP Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)CC1 URGJWIFLBWJRMF-JGVFFNPUSA-N 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000007850 degeneration Effects 0.000 description 1
- 230000002939 deleterious effect Effects 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 231100000676 disease causative agent Toxicity 0.000 description 1
- 239000002612 dispersion medium Substances 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 239000002158 endotoxin Substances 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 238000006911 enzymatic reaction Methods 0.000 description 1
- 102000013165 exonuclease Human genes 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 210000003754 fetus Anatomy 0.000 description 1
- 238000013467 fragmentation Methods 0.000 description 1
- 238000006062 fragmentation reaction Methods 0.000 description 1
- 108010074605 gamma-Globulins Proteins 0.000 description 1
- 238000012215 gene cloning Methods 0.000 description 1
- 238000012239 gene modification Methods 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 230000005017 genetic modification Effects 0.000 description 1
- 235000013617 genetically modified food Nutrition 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 231100000283 hepatitis Toxicity 0.000 description 1
- 229920001519 homopolymer Polymers 0.000 description 1
- 230000004727 humoral immunity Effects 0.000 description 1
- 125000001165 hydrophobic group Chemical group 0.000 description 1
- 230000003053 immunization Effects 0.000 description 1
- 238000002649 immunization Methods 0.000 description 1
- 230000005847 immunogenicity Effects 0.000 description 1
- 230000016784 immunoglobulin production Effects 0.000 description 1
- 230000000415 inactivating effect Effects 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 239000012678 infectious agent Substances 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 239000007951 isotonicity adjuster Substances 0.000 description 1
- 230000002147 killing effect Effects 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 229920006008 lipopolysaccharide Polymers 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- WSFSSNUMVMOOMR-NJFSPNSNSA-N methanone Chemical compound O=[14CH2] WSFSSNUMVMOOMR-NJFSPNSNSA-N 0.000 description 1
- 210000004897 n-terminal region Anatomy 0.000 description 1
- JPXMTWWFLBLUCD-UHFFFAOYSA-N nitro blue tetrazolium(2+) Chemical compound COC1=CC(C=2C=C(OC)C(=CC=2)[N+]=2N(N=C(N=2)C=2C=CC=CC=2)C=2C=CC(=CC=2)[N+]([O-])=O)=CC=C1[N+]1=NC(C=2C=CC=CC=2)=NN1C1=CC=C([N+]([O-])=O)C=C1 JPXMTWWFLBLUCD-UHFFFAOYSA-N 0.000 description 1
- 238000010899 nucleation Methods 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 210000001539 phagocyte Anatomy 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 230000003169 placental effect Effects 0.000 description 1
- 229920002401 polyacrylamide Polymers 0.000 description 1
- 229940085678 polyethylene glycol 8000 Drugs 0.000 description 1
- 235000019446 polyethylene glycol 8000 Nutrition 0.000 description 1
- 229920005862 polyol Polymers 0.000 description 1
- 150000003077 polyols Chemical class 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 229920006316 polyvinylpyrrolidine Polymers 0.000 description 1
- 230000004481 post-translational protein modification Effects 0.000 description 1
- 230000001323 posttranslational effect Effects 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 238000000164 protein isolation Methods 0.000 description 1
- 230000017854 proteolysis Effects 0.000 description 1
- 230000006337 proteolytic cleavage Effects 0.000 description 1
- 101150079601 recA gene Proteins 0.000 description 1
- 230000006798 recombination Effects 0.000 description 1
- 238000005215 recombination Methods 0.000 description 1
- 230000003362 replicative effect Effects 0.000 description 1
- 210000003705 ribosome Anatomy 0.000 description 1
- 235000019515 salmon Nutrition 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 238000000527 sonication Methods 0.000 description 1
- 229940063673 spermidine Drugs 0.000 description 1
- 239000008174 sterile solution Substances 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 230000000153 supplemental effect Effects 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000010189 synthetic method Methods 0.000 description 1
- 229960002180 tetracycline Drugs 0.000 description 1
- 229930101283 tetracycline Natural products 0.000 description 1
- 235000019364 tetracycline Nutrition 0.000 description 1
- 150000003522 tetracyclines Chemical class 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 108700012359 toxins Proteins 0.000 description 1
- 230000001131 transforming effect Effects 0.000 description 1
- 230000014621 translational initiation Effects 0.000 description 1
- 201000008297 typhoid fever Diseases 0.000 description 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
- 241000701161 unidentified adenovirus Species 0.000 description 1
- 241001515965 unidentified phage Species 0.000 description 1
- 229940125575 vaccine candidate Drugs 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 108700026220 vif Genes Proteins 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/22—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Neisseriaceae (F)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/095—Neisseria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P21/00—Preparation of peptides or proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Biochemistry (AREA)
- Medicinal Chemistry (AREA)
- Microbiology (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Physics & Mathematics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Gastroenterology & Hepatology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Plant Pathology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Immunology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US12472787A | 1987-11-24 | 1987-11-24 | |
| US24275888A | 1988-09-09 | 1988-09-09 | |
| PCT/US1988/004225 WO1989004873A1 (en) | 1987-11-24 | 1988-11-23 | Production of gonorrheal pi proteins and vaccines |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| NO902251D0 NO902251D0 (no) | 1990-05-22 |
| NO902251L NO902251L (no) | 1990-07-18 |
| NO302622B1 true NO302622B1 (no) | 1998-03-30 |
Family
ID=26822891
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO902251A NO302622B1 (no) | 1987-11-24 | 1990-05-22 | Rekombinant vektor, vertsorganisme, fremgangsmåte for fremstilling av et fullengde PIA protein fra Neisseria gonorrhoeae |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US5736361A (de) |
| EP (2) | EP0395706B1 (de) |
| JP (2) | JP2803058B2 (de) |
| KR (1) | KR970011309B1 (de) |
| AT (1) | ATE169958T1 (de) |
| AU (1) | AU629807B2 (de) |
| CA (1) | CA1340506C (de) |
| DE (1) | DE3856240T2 (de) |
| DK (1) | DK175831B1 (de) |
| FI (1) | FI102189B (de) |
| NO (1) | NO302622B1 (de) |
| WO (1) | WO1989004873A1 (de) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA1340506C (en) * | 1987-11-24 | 1999-04-20 | Nicholas H. Carbonetti | Production of gonorrheal pi proteins and vaccines |
| US7118757B1 (en) * | 1988-12-19 | 2006-10-10 | Wyeth Holdings Corporation | Meningococcal class 1 outer-membrane protein vaccine |
| ATE174625T1 (de) * | 1991-03-14 | 1999-01-15 | Imclone Systems Inc | Rekombinante hybride porinepitope |
| WO1995004133A1 (en) * | 1993-07-30 | 1995-02-09 | The University Of North Carolina At Chapel Hill | Production of gonorrheal pi proteins and vaccines in e. coli and salmonella |
| US7252828B2 (en) | 1998-07-15 | 2007-08-07 | The Brigham And Women's Hospital, Inc. | Polysaccharide vaccine for staphylococcal infections |
| SK16022001A3 (sk) * | 1999-05-13 | 2002-09-10 | American Cyanamid Company | Adjuvantné kombinované prostriedky |
| CA2386025A1 (en) * | 1999-09-30 | 2001-04-05 | Isis Innovation Limited | Vaccine against neisseria infection |
| CA2875231A1 (en) * | 2000-02-28 | 2001-09-07 | Novartis Vaccines And Diagnostics S.R.L. | Heterologous expression of neisserial proteins |
| CA2429000A1 (en) * | 2000-11-10 | 2002-05-16 | Wyeth Holdings Corporation | Adjuvant combination formulations |
| CN100351260C (zh) | 2002-11-12 | 2007-11-28 | 布赖汉姆妇女医院 | 葡萄球菌感染的多糖疫苗 |
| EP1583517B1 (de) | 2002-11-12 | 2019-06-12 | The Brigham And Women's Hospital, Inc. | Verfahren und produkte zur behandlung von infektionen mit staphylokokken |
| CN101001874B (zh) | 2004-04-21 | 2012-12-19 | 布赖汉姆妇女医院 | 聚-n-乙酰葡萄糖胺(pnag/dpnag)结合肽及其应用方法 |
| US7037698B2 (en) | 2004-05-19 | 2006-05-02 | Amano Enzyme Inc. | Pyrroloquinoline quinone-dependent glucose dehydrogenase |
| ES2660594T3 (es) | 2008-07-21 | 2018-03-23 | The Brigham And Women's Hospital, Inc. | Métodos y composiciones relacionados con oligosacáridos sintéticos de beta-1,6 glucosamina |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4237224A (en) * | 1974-11-04 | 1980-12-02 | Board Of Trustees Of The Leland Stanford Jr. University | Process for producing biologically functional molecular chimeras |
| US4203971A (en) * | 1978-03-23 | 1980-05-20 | Government Of The United States | Neisseria gonorrhoeae vaccine |
| DE2814039C3 (de) * | 1978-03-31 | 1981-02-19 | Gesellschaft Fuer Biotechnologische Forschung Mbh (Gbf), 3300 Braunschweig | Verfahren zur Herstellung von Hybrid-Bakterien |
| US4351761A (en) * | 1978-05-15 | 1982-09-28 | Research Corporation | Purified antigen to test for Neisseria gonorrhoeae antibodies |
| US4220638A (en) * | 1978-10-12 | 1980-09-02 | Merck & Co., Inc. | Antigenic complex from N. Gonorrhoeae |
| US4288557A (en) * | 1978-10-12 | 1981-09-08 | Merck & Co., Inc. | Antigenic complex from N. gonorrhoeae |
| US4239749A (en) * | 1979-09-27 | 1980-12-16 | United States Of America | Neisseria gonorrhoeae vaccine |
| FI63596C (fi) * | 1981-10-16 | 1983-07-11 | Orion Yhtymae Oy | Mikrobdiagnostiskt foerfarande som grundar sig pao skiktshybridisering av nukleinsyror och vid foerfarandet anvaenda kombinationer av reagenser |
| WO1983003354A1 (en) * | 1982-03-30 | 1983-10-13 | Us Army | Neisseria gonorrhoeae vaccine |
| EP0178863A1 (de) * | 1984-10-15 | 1986-04-23 | Schering Corporation | Expressionssysteme die sich der Bakteriophage-T7-Promotoren bedienen und Gensequenzen |
| US4681761A (en) * | 1985-10-24 | 1987-07-21 | State Of Oregon, Acting By And Through The Oregon State Board Of Higher Education, Acting For And On Behalf Of The Oregon Health Sciences University | Major iron-regulated protein of Neisseria gonorrhoeae and its use as vaccine |
| US4786592A (en) * | 1986-06-18 | 1988-11-22 | Scripps Clinic And Research Foundation | Neisseria gonorrhoeae lectin useful as a vaccine and diagnostic marker and means for producing this lectin |
| CA1340506C (en) * | 1987-11-24 | 1999-04-20 | Nicholas H. Carbonetti | Production of gonorrheal pi proteins and vaccines |
-
1988
- 1988-11-22 CA CA000583787A patent/CA1340506C/en not_active Expired - Fee Related
- 1988-11-23 AT AT89900540T patent/ATE169958T1/de not_active IP Right Cessation
- 1988-11-23 KR KR1019890701369A patent/KR970011309B1/ko not_active IP Right Cessation
- 1988-11-23 WO PCT/US1988/004225 patent/WO1989004873A1/en active IP Right Grant
- 1988-11-23 AU AU27959/89A patent/AU629807B2/en not_active Expired
- 1988-11-23 DE DE3856240T patent/DE3856240T2/de not_active Expired - Lifetime
- 1988-11-23 JP JP1500595A patent/JP2803058B2/ja not_active Expired - Lifetime
- 1988-11-23 EP EP89900540A patent/EP0395706B1/de not_active Expired - Lifetime
- 1988-11-23 EP EP98101882A patent/EP0869133A1/de not_active Withdrawn
-
1990
- 1990-05-22 NO NO902251A patent/NO302622B1/no unknown
- 1990-05-23 DK DK199001284A patent/DK175831B1/da not_active IP Right Cessation
- 1990-05-23 FI FI902569A patent/FI102189B/fi not_active IP Right Cessation
-
1992
- 1992-12-01 US US07/983,995 patent/US5736361A/en not_active Expired - Fee Related
-
1997
- 1997-11-06 US US08/965,085 patent/US6068992A/en not_active Expired - Fee Related
-
1998
- 1998-01-22 JP JP04415498A patent/JP3388171B2/ja not_active Expired - Lifetime
Also Published As
| Publication number | Publication date |
|---|---|
| JPH10234388A (ja) | 1998-09-08 |
| KR890701750A (ko) | 1989-12-21 |
| US5736361A (en) | 1998-04-07 |
| NO902251L (no) | 1990-07-18 |
| DE3856240D1 (de) | 1998-09-24 |
| DK128490D0 (da) | 1990-05-23 |
| FI902569A0 (fi) | 1990-05-23 |
| AU629807B2 (en) | 1992-10-15 |
| DK128490A (da) | 1990-07-06 |
| JPH03502881A (ja) | 1991-07-04 |
| FI102189B1 (fi) | 1998-10-30 |
| FI102189B (fi) | 1998-10-30 |
| WO1989004873A1 (en) | 1989-06-01 |
| EP0395706A1 (de) | 1990-11-07 |
| DK175831B1 (da) | 2005-03-14 |
| DE3856240T2 (de) | 1999-05-06 |
| JP3388171B2 (ja) | 2003-03-17 |
| KR970011309B1 (ko) | 1997-07-09 |
| EP0395706B1 (de) | 1998-08-19 |
| AU2795989A (en) | 1989-06-14 |
| ATE169958T1 (de) | 1998-09-15 |
| NO902251D0 (no) | 1990-05-22 |
| US6068992A (en) | 2000-05-30 |
| JP2803058B2 (ja) | 1998-09-24 |
| EP0869133A1 (de) | 1998-10-07 |
| EP0395706A4 (en) | 1991-11-13 |
| CA1340506C (en) | 1999-04-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2685442B2 (ja) | ボルデテラ・パータツシス染色体ＤＮＡのＥｃｏＲＩフラグメント | |
| EP1066375B1 (de) | Lactobacilli, die aggregations und mucin bindende gene als traeger von vakzinen enthalten | |
| KR100188323B1 (ko) | 비타입성 헤모필루스 인플렌자에 대한 백신 | |
| EP0558631B1 (de) | Rekombinante avirulente salmonella antifruchtbarkeitsimpfstoffe | |
| Burnette et al. | Direct expression of Bordetelia pertussis toxin subunits to high levels in Escherichia coli | |
| JPH08503602A (ja) | 弱毒化細菌における組換え融合タンパク質の発現 | |
| NO302622B1 (no) | Rekombinant vektor, vertsorganisme, fremgangsmåte for fremstilling av et fullengde PIA protein fra Neisseria gonorrhoeae | |
| JP2004337170A (ja) | ヘリコバクター感染に対する免疫原性組成物、該組成物に用いられるポリぺプチドおよび該ポリぺプチドをコードする核酸配列 | |
| EP0294469B1 (de) | Impfstoffe und diagnosetest für haemophilus influenzae | |
| US5288617A (en) | Method of producing an antigenic preparation | |
| KR0170752B1 (ko) | 혈호균속 인플루엔자용 백신과 진단검사법 | |
| Sirard et al. | A recombinant Bacillus anthracis strain producing the Clostridium perfringens Ib component induces protection against iota toxins | |
| Goldschmidt et al. | Regions of the Streptococcus sobrinus spaA gene encoding major determinants of antigen I | |
| US6348332B1 (en) | DNA molecule encoding gonorrhoeal hybrid PIA/PIB protein | |
| WO1986002557A1 (en) | Improved antigenic preparation | |
| EP0358692B1 (de) | Impfstoff gegen cholera | |
| WO1992016223A1 (en) | Production of gonorrheal pi proteins and vaccines | |
| JP2004529601A (ja) | 組換えインフルエンザ菌アドヘシンタンパク質 | |
| WO1994006911A2 (en) | Mycoplasma pulmonis antigens and methods and compositions for use in cloning and vaccination | |
| HU222982B1 (hu) | Heterológ proteinek kifejezése attenuált baktériumokban htrA promoter alkalmazásával | |
| EP0419997A1 (de) | Klonierung des für die pilinische Untereinheit fim3 kodierenden Gens von Bordetella pertussis | |
| Kawula | Molecular biology of Neisseria meningitidis class 5 and H. 8 outer membrane proteins | |
| JPH11501203A (ja) | 大腸菌およびサルモネラ菌中における淋菌ｐｉタンパクおよびワクチンの製造 |